Ervebo + Inmazeb
Phase 2Recruiting 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Ebola Virus Disease
Conditions
Ebola Virus Disease
Trial Timeline
Jan 1, 2027 → Aug 1, 2027
NCT ID
NCT05202288About Ervebo + Inmazeb
Ervebo + Inmazeb is a phase 2 stage product being developed by Regeneron Pharmaceuticals for Ebola Virus Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05202288. Target conditions include Ebola Virus Disease.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05202288 | Phase 2 | Recruiting |
Competing Products
20 competing products in Ebola Virus Disease